← Surfer · Sage hub

Sage — Eye: Organ Dysfunction (Ocular Archetype)

Surfer Coach Sage

Named ocular phenotypes are treated first as long-running expressions of how energy-hungry ocular tissues fail — or compensate — when cellular energy transduction is strained. Stay monist: Shore / Surf Judge language names orientation inside one field — not a second “mind stuff” beside mitochondria, and not a morality play in which pressure, VEGF, or drusen invent evil independent of cellular fuel handling.

Introduction: One engine, many named eye diseases

This essay proposes that chronic diseases of modernity share a common upstream driver: persistent cellular bioenergetic insufficiency rooted in mitochondrial dysfunction. That framing was already applied to atherosclerosis, cancer, aging, immune dysfunction, and cell signaling. Here it extends to organ dysfunction — using the eye, given its exceptional metabolic demands, clinical accessibility, and ophthalmic practice context, as the primary archetype and diagnostic window. The same logic applies with equal force to heart, kidney, brain, and virtually every other organ system.

In this hypothesis, what conventional models label as distinct organ-specific diseases — age-related macular degeneration (AMD), diabetic retinopathy (DR), primary open-angle glaucoma, dry eye disease (DED), cataract, and their systemic counterparts — may be better understood as higher-order compensatory mechanisms or their eventual failure, attempting to restore or defend level 0–1 persistence when primary cellular energy production in critical parenchymal and support cells falters chronically.

Level 0–1 persistence is the fundamental cellular striving for persistence: adequate ATP production, redox balance, and metabolic homeostasis centered on mitochondria. Organs are integrated tissue-level assemblies where specialized cells perform high-work functions supported by vascular, extracellular-matrix, and local signaling networks. When level 0–1 fails in key cell populations — fuel inefficiency (peroxidized cardiolipin, proposed here to come from seed-oil PUFAs, impairing ETC in high-PUFA membranes; hyperglycemia stressing mitochondria via ROS and substrate overload; nutrient deficiencies for ETC cofactors and biogenesis; circadian misalignment, which in mice disrupts PGC-1α-linked rhythms), elevated ROS, accumulated mtDNA damage, or impaired mitophagy — higher-level organ responses may activate: vascular remodeling (angiogenesis or rarefaction), extracellular-matrix reorganization, altered fluid dynamics, local immune activation for debris clearance, and functional adaptation or sacrifice of vulnerable cell types. In this model, acute activation can be adaptive; chronic persistence or misdirection would reflect ongoing level 0–1 deficit and failed resolution — not primary “organ failure” or inevitable senescence per se.

Conventional ophthalmology: powerful local tools, incomplete upstream story

On Sage — Ophthalmology.

The eye as high-stakes model of organ-level compensation

The retina and supporting structures illustrate the principle with unusual clarity because of extreme bioenergetic requirements. The retina is among the most energy-hungry tissues in the body, and photoreceptor inner segments are its dominant oxygen consumers; daily phagocytosis of outer-segment disks by RPE, the visual cycle, blood–retina barrier maintenance, and continuous phototransduction and ion pumping demand robust mitochondrial capacity. The fovea is avascular, relying on choroidal diffusion; retinal vessels are tightly autoregulated. High PUFA content — particularly DHA in photoreceptor membranes — confers fluidity for signaling but may create vulnerability to peroxidation if antioxidant systems or ETC efficiency falter. Lifelong cumulative light exposure, especially short-wavelength, adds photooxidative load. In this context, chronic level 0–1 insufficiency — systemic metabolic disease, dietary seed-oil incorporation into cardiolipin, blue-light/circadian disruption of repair rhythms, or age-related biogenesis decline — is proposed to trigger organ-level responses visible as “disease.”

The Good Doctor names the same readability: the eye is optically open, functionally testable in minutes, and expensive in energy. Photoreceptors, RGCs, and trabecular meshwork have little slack. What the rest of the body whispers, the eye sometimes says early. A macular hole, endophthalmitis, or melanoma are not “mismatch” — they are local events with local clocks. The claim is narrower: a large fraction of chronic ocular disease is the eye-shaped end of a systemic compensatory state. Peptides and drops can slow a curve; the larger reserve is whether the person can again generate energy without constant emergency signaling.

AMD: compensatory debris clearance and perfusion restoration

In AMD, stressed or senescent RPE cells show mtDNA damage, and RPE cultured from AMD donors shows reduced mitochondrial function, with impaired autophagy and higher ROS under stress in one study; reduced phagocytic efficiency has also been proposed. Incomplete digestion and clearance of photoreceptor outer segments and other debris is thought to contribute to accumulation of lipofuscin, oxidized lipids, and proteins in Bruch’s membrane and sub-RPE space — the drusen and basal laminar deposits that define early and intermediate AMD. Complement activation and low-grade inflammation may represent higher-level immune compensation attempting to clear waste and signal repair; in genetically susceptible individuals (e.g., CFH variants interacting with oxidative substrate), this may become chronic and bystander-damaging. Choriocapillaris rarefaction or endothelial dysfunction (possibly mitochondrial) may create relative hypoxia or nutrient-diffusion barriers for the outer retina. In this model, the compensatory response is choroidal neovascularization — VEGF-driven angiogenesis attempting to restore perfusion and delivery of oxygen, glucose, and other substrates to energy-starved photoreceptors and RPE. In wet AMD this membrane leaks, causing exudation, hemorrhage, and fibrosis (disciform scar as maladaptive “repair”), but the drive itself may be a logical higher-level attempt to solve a delivery problem created by level 0–1 failure. Geographic atrophy may represent burnout of this compensation, excessive phagocytic or inflammatory clearance of stressed RPE, or terminal energy failure. Conventional focus on complement inhibition or anti-VEGF targets the compensation (or its excess) and, in this view, leaves a proposed underlying RPE/photoreceptor mitochondrial insufficiency unaddressed; progression of atrophy or fellow-eye involvement often continues. Good Doctor, in brief: deposits are not the first cause — they are what failed cleanup looks like.

Diabetic retinopathy: ischemic compensation and neurovascular failure

DR provides perhaps the clearest clinical example. Chronic hyperglycemia, especially (on this hypothesis) with underlying mitochondrial inflexibility, drives excessive ROS in vascular endothelial cells via mitochondrial overload, and plausibly in retinal pericytes and neurons. Pericytes are lost, possibly through energy failure and apoptosis, leading to capillary-wall instability, microaneurysms, and eventual acellular capillaries with non-perfusion. Retinal ischemia triggers a robust compensatory VEGF response that produces neovascularization (proliferative DR) and increased vascular permeability (diabetic macular edema) — in this model, not random pathology but attempts to restore nutrient and oxygen delivery. Simultaneously, early inner-retinal neurodegeneration, possibly from direct mitochondrial dysfunction in RGCs, bipolar cells, and photoreceptors, can be detected by OCT RNFL/GCL thinning and functional ERG changes (delayed implicit times, reduced oscillatory potentials), sometimes before overt vasculopathy. Conventional management — intensive glycemic control (helpful but incomplete; legacy effects), anti-VEGF, laser, vitrectomy — stabilizes vision-threatening complications but is not aimed at cellular bioenergetic capacity and does not fully prevent progression under long-standing metabolic dysfunction. The metabolic hypothesis predicts that interventions improving mitochondrial fuel flexibility and reducing ROS (shifting away from chronic high-glucose flux; supporting ETC cofactors) would reduce ischemic drive and neurovascular stress upstream of VEGF. Good Doctor, in brief: anti-VEGF treats a downstream angiogenesis — it does not explain why the retina asked for vessels.

Glaucoma: energy-dependent axonal transport at the lamina cribrosa

On Sage — Glaucoma.

Dry eye and cataract as glandular and lenticular energy failures

Dry eye — more common with aging and possibly with screen use and metabolic syndrome — involves energy-dependent processes at multiple sites: lacrimal acinar cells for protein synthesis, ion transport, and fluid secretion; meibomian glands for holocrine lipid secretion; ocular-surface epithelium and goblet cells for tight junctions and mucin. In this model, mitochondrial dysfunction — systemic factors, local oxidative stress, or androgen decline affecting gland energy metabolism — may lead to reduced tear volume/quality, evaporative loss, and compensatory inflammation that attempts to signal repair but often perpetuates damage. Lubricants, anti-inflammatories, meibomian expression, and punctal occlusion relieve symptoms and some improve gland or surface function, but on this hypothesis they do not by themselves address the upstream energy shortfall. More on Sage — Ocular Surface.

This model proposes that cataract reflects, at least in part, lenticular epithelial mitochondrial insufficiency. Lens epithelial cells maintain redox balance, ion pumps, and antioxidant systems for underlying fiber cells that lose organelles early in differentiation. Cumulative oxidative damage from UV, hyperglycemia, or systemic ROS, possibly amplified by declining mito capacity with age, oxidizes crystallins, disrupts membranes, and causes protein aggregation and light scattering. Diabetic cataract accelerates via polyol pathway and glycation possibly compounding mito stress. Phacoemulsification with IOL is highly effective for visual rehabilitation but does not prevent fellow-eye progression or address systemic metabolic drivers evident in higher cataract rates among diabetics, with the excess risk greatest at younger ages, and among those with metabolic syndrome.

Inherited retinal disease and retinoblastoma

On Sage — Retinitis Pigmentosa, Retinoblastoma, and Inherited Retinal Disease.

Parallels: heart, kidney, brain

The same hierarchical logic operates in other high-energy organs — cardiomyocyte mito density and compensatory hypertrophy/fibrosis; proximal tubular / podocyte energy failure and scarring; neuronal axonal transport, calcium buffering, and protein mishandling analogous to retinal drusen. The eye is archetype and early-warning system, not a separate ontology. Cardiac, kidney, and brain topics have their own Sage pages.

Implications: engine stewardship beside specialty tools

Conventional models have produced remarkable organ-specific advances. Yet they treat each organ’s manifestations as semi-autonomous without systematic attention to why cellular energy capacity declined or why compensatory mechanisms become maladaptive. That may contribute to polypharmacy, repeated procedures, and incomplete modification for residual progression or multimorbidity.

The model predicts that restoring level 0–1 efficiency across tissues will reduce the need for and burden of organ-level compensation. Testable avenues named in Organ Dysfunction:

  • Fuel / Circadian / Strength (foundational EnSurf): minimize seed-oil PUFAs, which this model proposes peroxidize cardiolipin in vulnerable membranes such as retina and endothelium, though human evidence linking dietary linoleic acid to AMD is mixed; include animal fats and proteins for bioavailable nutrients and stable substrates; fermented MACs for gut–mito axis; morning outdoor light, consistent sleep and feeding windows to entrain mitochondrial biogenesis rhythms; dynamic strength training (PGC-1α-driven biogenesis, mitophagy, myokines).
  • Adjunctive metabolic support beside ophthalmology: bioenergetic proxies (grip, HRV/sleep metrics, CGM/ketone flexibility); in eye, serial ERG (e.g., Reteval) for retinal electrical function, a proposed but not yet validated metabolic proxy, OCT for structural proxies. Time-restricted eating or ketogenic/carnivore phases as hypothesis terrain to shift fuel preference and reduce chronic glucose-driven mito ROS — never unsupervised protocol theater. Cofactors supporting ETC and antioxidant defense (CoQ10, PQQ, B vitamins, magnesium, creatine) considered as research-adjacent support language in the essays — not a retail shopping list or Surfer dose schedule. In established ocular disease these may complement rather than replace standard care, potentially reducing injection frequency or progression rates — invitation to testing, not a claim of proven replacement.
  • Research: stratify by mitochondrial function or metabolic flexibility alongside conventional staging; longitudinal links of bioenergetic metrics to incident AMD, DR progression, glaucoma conversion, or treatment response; upstream metabolic optimization in early/at-risk populations. Developing BioEye/BioVision biosensor concepts aim at non-invasive windows into local and perhaps systemic bioenergetics — named as concepts in Organ Dysfunction; the hardware is named only, with no claim made.

Repositioning, not rejection: use pharmaceuticals, biologics, and surgery judiciously for acute vision-threatening complications, bridging, or rapid functional restoration, while prioritizing root restoration of cellular energy economy — especially in chronic, slowly progressive, or prevention settings.

Testable orientation

  • Restoring level 0–1 efficiency should reduce need for chronic organ-level compensation and slow incidence/progression of AMD, DR, glaucoma conversion, and related phenotypes — beyond what local effector targeting alone predicts.
  • Bioenergetic proxies (grip, metabolic flexibility; serial ERG / OCT as ocular windows) should track trajectories alongside conventional staging.
  • IOP lowering remains often necessary as mechanical-margin therapy; durability and field preservation should improve when mitochondrial headroom is concurrently restored — hypothesis, not a trial verdict that lifestyle replaces drops.
  • Anti-VEGF and related tools remain bridges for vision-threatening angiogenesis; upstream mito/fuel work should reduce the ischemic or energy-starved drive that asks for vessels — again invitation to rigorous testing.

Limits of the claim

  • Working hypothesis. Not a randomized-trial verdict that mitochondrial-first strategies outperform guideline ophthalmology as monotherapy.
  • Does not deny clinical necessity of IOP-lowering, anti-VEGF, laser, vitrectomy, cataract surgery, infection care, trauma care, or oncology; does not authorize stopping them from a webpage.
  • Local acute events (macular hole, endophthalmitis, melanoma, retinal detachment) are not reframed as “mismatch.”
  • No dualism.

Conclusion: the failing organ is the alarm

In this hypothesis, organ dysfunction in the eye and throughout the body is understood most coherently as the clinical expression of cellular persistence failure when higher-level compensatory systems — vascular remodeling, matrix reorganization, local immune activation, fluid and pressure dynamics, and functional adaptation — are chronically activated, overwhelmed, or misdirected by persistent mitochondrial bioenergetic insufficiency. The eye, with its high metabolic rate, post-mitotic longevity, and clinical observability, may serve as both archetype and early-warning system. The failing organ — whether vision loss, heart failure, declining GFR, or cognitive change — is, in this hypothesis, the downstream alarm; the mitochondrial insufficiency it may have evolved to signal and compensate for is what we must ultimately address.

Coach and Surfer give shorter versions. Ophthalmology still owns diagnosis, procedure clocks, and acute rescue.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 31, 2026.

References

  1. Paradies G, Paradies V, De Benedictis V, et al., 2014. Functional role of cardiolipin in mitochondrial bioenergetics. Biochimica et Biophysica Acta - Bioenergetics 1837(4):408-417. doi:10.1016/j.bbabio.2013.10.006
  2. Brownlee M, 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865):813-820. doi:10.1038/414813a
  3. Liu C, Li S, Liu T, et al., 2007. Transcriptional coactivator PGC-1alpha integrates the mammalian clock and energy metabolism. Nature 447(7143):477-481. doi:10.1038/nature05767
  4. Rosenfeld PJ, Brown DM, Heier JS, et al., 2006. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 355(14):1419-1431. doi:10.1056/NEJMoa054481
  5. Mitchell P, Liew G, Gopinath B, et al., 2018. Age-related macular degeneration. The Lancet 392(10153):1147-1159. doi:10.1016/S0140-6736(18)31550-2
  6. Wong-Riley MT, 2010. Energy metabolism of the visual system. Eye and Brain 2:99-116. doi:10.2147/EB.S9078
  7. Yu DY, Cringle SJ, 2001. Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Progress in Retinal and Eye Research 20(2):175-208. doi:10.1016/s1350-9462(00)00027-6
  8. Strauss O, 2005. The retinal pigment epithelium in visual function. Physiological Reviews 85(3):845-881. doi:10.1152/physrev.00021.2004
  9. Provis JM, Dubis AM, Maddess T, et al., 2013. Adaptation of the central retina for high acuity vision: cones, the fovea and the avascular zone. Progress in Retinal and Eye Research 35:63-81. doi:10.1016/j.preteyeres.2013.01.005
  10. Pournaras CJ, Rungger-Brändle E, Riva CE, et al., 2008. Regulation of retinal blood flow in health and disease. Progress in Retinal and Eye Research 27(3):284-330. doi:10.1016/j.preteyeres.2008.02.002
  11. SanGiovanni JP, Chew EY, 2005. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Progress in Retinal and Eye Research 24(1):87-138. doi:10.1016/j.preteyeres.2004.06.002
  12. Wu J, Seregard S, Algvere PV, 2006. Photochemical damage of the retina. Survey of Ophthalmology 51(5):461-481. doi:10.1016/j.survophthal.2006.06.009
  13. Terluk MR, Kapphahn RJ, Soukup LM, et al., 2015. Investigating mitochondria as a target for treating age-related macular degeneration. The Journal of Neuroscience 35(18):7304-7311. doi:10.1523/JNEUROSCI.0190-15.2015
  14. Klein RJ, Zeiss C, Chew EY, et al., 2005. Complement factor H polymorphism in age-related macular degeneration. Science 308(5720):385-389. doi:10.1126/science.1109557
  15. Weismann D, Hartvigsen K, Lauer N, et al., 2011. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478(7367):76-81. doi:10.1038/nature10449
  16. Mullins RF, Johnson MN, Faidley EA, et al., 2011. Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration. Investigative Ophthalmology & Visual Science 52(3):1606-1612. doi:10.1167/iovs.10-6476
  17. Rofagha S, Bhisitkul RB, Boyer DS, et al., 2013. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120(11):2292-2299. doi:10.1016/j.ophtha.2013.03.046
  18. Grunwald JE, Pistilli M, Daniel E, et al., 2017. Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 124(1):97-104. doi:10.1016/j.ophtha.2016.09.012
  19. Liao DS, Grossi FV, El Mehdi D, et al., 2020. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Ophthalmology 127(2):186-195. doi:10.1016/j.ophtha.2019.07.011
  20. Hammes HP, Lin J, Renner O, et al., 2002. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51(10):3107-3112. doi:10.2337/diabetes.51.10.3107
  21. Aiello LP, Avery RL, Arrigg PG, et al., 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine 331(22):1480-1487. doi:10.1056/NEJM199412013312203
  22. Sohn EH, van Dijk HW, Jiao C, et al., 2016. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proceedings of the National Academy of Sciences of the USA 113(19):E2655-E2664. doi:10.1073/pnas.1522014113
  23. Harrison WW, Bearse MA Jr, Ng JS, et al., 2011. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Investigative Ophthalmology & Visual Science 52(2):772-777. doi:10.1167/iovs.10-5931
  24. Diabetes Control and Complications Trial Research Group, 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329(14):977-986. doi:10.1056/NEJM199309303291401
  25. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, 2000. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. New England Journal of Medicine 342(6):381-389. doi:10.1056/NEJM200002103420603
  26. Truscott RJ, 2005. Age-related nuclear cataract-oxidation is the key. Experimental Eye Research 80(5):709-725. doi:10.1016/j.exer.2004.12.007
  27. Kiziltoprak H, Tekin K, Inanc M, et al., 2019. Cataract in diabetes mellitus. World Journal of Diabetes 10(3):140-153. doi:10.4239/wjd.v10.i3.140
  28. Liu YC, Wilkins M, Kim T, et al., 2017. Cataracts. The Lancet 390(10094):600-612. doi:10.1016/S0140-6736(17)30544-5
  29. Pilegaard H, Saltin B, Neufer PD, 2003. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. The Journal of Physiology 546(Pt 3):851-858. doi:10.1113/jphysiol.2002.034850
  30. Ferrington DA, Ebeling MC, Kapphahn RJ, et al., 2017. Altered bioenergetics and enhanced resistance to oxidative stress in human retinal pigment epithelial cells from donors with age-related macular degeneration. Redox Biology 13:255-265. doi:10.1016/j.redox.2017.05.015
  31. Golestaneh N, Chu Y, Xiao YY, et al., 2017. Dysfunctional autophagy in RPE, a contributing factor in age-related macular degeneration. Cell Death & Disease 8(1):e2537. doi:10.1038/cddis.2016.453
  32. Becker C, Schneider C, Aballéa S, et al., 2018. Cataract in patients with diabetes mellitus-incidence rates in the UK and risk factors. Eye 32(6):1028-1035. doi:10.1038/s41433-017-0003-1
  33. Sabanayagam C, Wang JJ, Mitchell P, et al., 2011. Metabolic syndrome components and age-related cataract: the Singapore Malay eye study. Investigative Ophthalmology & Visual Science 52(5):2397-2404. doi:10.1167/iovs.10-6373

See the notice at the top of this page. Working hypothesis, not medical advice. Essay draws from grounded mechanisms in Organ Dysfunction and Good Doctor as of 2026 — individual care requires personalized evaluation by a qualified physician.